EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer

Victoria Mohring, Marie Ancion, Pascale Hubert, Fanny Lardinois, Martin Bizet, David Stern, Maude A Liegeois, Patrick Roncarati, Ferman Agirman, Naïma Maloujahmoum, Justine Bellier, Tom Wissocq und 6 weitere

Journal for ImmunoTherapy of Cancer · 2026-08 · 14 (8) · e014841

DOI: 10.1136/jitc-2026-014841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 13.08.2026. Verfasst von Victoria Mohring und 17 weiteren Autor:innen. Beteiligte Einrichtung: Metastasis Research Laboratory, GIGA Research Institute, University of Liège, Liège, Belgium. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Pyruvaldehyde, Myeloid-Derived Suppressor Cells. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondation Léon Frédericq”, Université de Liège, FNRS-Télévie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic reprogramming through enhanced glycolysis is a hallmark of cancer that supports tumor progression and promotes protumor immune responses. Methylglyoxal (MG), a reactive by-product of glycolysis, has recently emerged as an oncometabolite implicated in cancer progression and therapy resistance. Our previous work demonstrated that an imbalance between MG production and detoxification by the glyoxalase system, referred to as MG stress, contributes to progression and metastatic dissemination in triple-negative breast cancer (TNBC). However, the impact of MG stress on the tumor immune microenvironment remains poorly understood.

Methods

Using two preclinical breast cancer models, we investigated the relationship between MG stress and immune modulation, with a focus on granulocytic myeloid-derived suppressor cells (g-MDSCs), major mediators of immune evasion. In silico analyses were performed to assess correlations between MG stress-related gene signatures and transcriptional markers of MDSC infiltration in patients with TNBC, as well as associations with anti-programmed cell death protein 1 (PD-1) immunotherapy response in melanoma cohorts. In vivo experiments combined the MG scavenger carnosine with PD-1 blockade in the immunotherapy-resistant 4T1 breast cancer model.

Results

MG stress was associated with the expansion of g-MDSCs in breast cancer models. Importantly, MG stress conferred metastatic potential to non-metastatic 67NR breast tumors, potentially through activation of the Nuclear Factor kappa B (NF-κB) pathway, increased granulocyte-macrophage colony-stimulating factor expression, and systemic expansion of g-MDSCs. In silico analyses revealed a positive correlation between MG stress-related gene signature and transcriptional markers of MDSC infiltration in patients with TNBC. Furthermore, this signature distinguished anti-PD-1 responder (low MG stress), from non-responders (high MG stress) in patients with melanoma. Therapeutically, combined targeting of MG stress with carnosine and PD-1 signaling significantly reduced g-MDSC accumulation in tumors, spleens, and lungs, and decreased lung metastatic burden in the 4T1 model.

Conclusions

These findings identify MG stress as a driver of an immunosuppressive tumor microenvironment that may impair immunotherapy efficacy and promote metastatic progression in TNBC. Dual targeting of MG stress and PD-1 signaling represents a promising therapeutic strategy to overcome immune suppression and limit metastasis in immunotherapy-resistant breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsPyruvaldehydeMyeloid-Derived Suppressor CellsAnimalsFemaleHumansMiceTumor MicroenvironmentMetabolic ReprogrammingNeoplasm MetastasisCell Line, Tumor

Stichwörter der Autor:innen

Breast CancerImmunosuppressionImmunotherapyTumor Microenvironment

Substanzen

Pyruvaldehyde

Autor:innen und Institutionen

  • Metastasis Research Laboratory, GIGA Research Institute, University of Liège, Liège, Belgium.
  • Experimental Pathology, GIGA Research Institute, University of Liège, Liège, Belgium.
  • Institute for Medical Immunology, Free University of Brussels, Brussels, Belgium.
  • GIGA Platforms -Genomics, University of Liège, Liège, Belgium.
  • Laboratory of Immunophysiology, University of Liège, Liège, Belgium.
  • Tumor Immunotherapy and Microenvironment, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg.

Förderung

  • Fondation Léon Frédericq”
  • Université de Liège
  • FNRS-Télévie
  • National Fund for Scientific Research (FNRS), Belgium

Zitieren

APA

Mohring, V., Ancion, M., Hubert, P., Lardinois, F., Bizet, M., Stern, D., Liegeois, M. A., Roncarati, P., Agirman, F., Maloujahmoum, N., Bellier, J., Wissocq, T., Nokin, M. J., Herfs, M., Rademaker, G., Peulen, O., Janji, B., & Bellahcene, A. (2026). Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer, 14(8), e014841. https://doi.org/10.1136/jitc-2026-014841

Vancouver

Mohring V, Ancion M, Hubert P, Lardinois F, Bizet M, Stern D, et al. Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 2026;14(8):e014841. doi:10.1136/jitc-2026-014841

BibTeX
@article{Mohring2026,
  author = {Mohring, Victoria and Ancion, Marie and Hubert, Pascale and Lardinois, Fanny and Bizet, Martin and Stern, David and Liegeois, Maude A and Roncarati, Patrick and Agirman, Ferman and Maloujahmoum, Naïma and Bellier, Justine and Wissocq, Tom and Nokin, Marie-Julie and Herfs, Michael and Rademaker, Gilles and Peulen, Olivier and Janji, Bassam and Bellahcene, Akeila},
  title = {Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {e014841},
  doi = {10.1136/jitc-2026-014841}
}
Kostenlos starten →